Cargando…
Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer
Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal variant of prostate cancer (PCa), and it remains a diagnostic challenge. Herein we report our findings of using synaptic vesicle glycoprotein 2 isoform A (SV2A) as a promising marker for positron emission tomography (PET) imaging of n...
Autores principales: | Guan, Bing, Zhou, Ning, Wu, Cheng-Yang, Li, Songye, Chen, Yu-An, Debnath, Sashi, Hofstad, Mia, Ma, Shihong, Raj, Ganesh V., He, Dalin, Hsieh, Jer-Tsong, Huang, Yiyun, Hao, Guiyang, Sun, Xiankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657802/ https://www.ncbi.nlm.nih.gov/pubmed/34884893 http://dx.doi.org/10.3390/ijms222313085 |
Ejemplares similares
-
A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer
por: Gonzalez, Paulina, et al.
Publicado: (2023) -
Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists
por: Debnath, Sashi, et al.
Publicado: (2022) -
The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC
por: Lee, Cheng‐Fan, et al.
Publicado: (2022) -
PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022) -
Preface
por: Hsieh, Jer-Tsong, et al.
Publicado: (2013)